Kidney360 published a case report and literature review on 4 September 2026 from the Division of Nephrology at the University of Maryland School of Medicine.

A 59-year-old woman with type 2 diabetes, taking metformin and tirzepatide, developed severe metformin-associated lactic acidosis together with ketoacidosis, while her glucose stayed relatively normal.

She was managed successfully with emergency sequential haemodialysis and high-dose continuous venovenous haemodiafiltration. The reason the authors wrote it up is what the near-normal glucose did to the picture.

A framing note. This is a clinical case report about approved medicines. Peptra Labs supplies Tirzepatide as a reference material for laboratory research only, and nothing below is guidance about human use, about any medicine or about any clinical decision.

The two conditions that arrived together on tirzepatide

Metformin-associated lactic acidosis, which the authors abbreviate as MALA, is uncommon and dangerous. They give an incidence of fewer than 10 cases per 100,000 patient-years and a mortality of 30 to 50 percent.

It most often occurs alongside acute kidney injury, which impairs metformin excretion. Accumulated metformin inhibits mitochondrial complex I, and pyruvate metabolism shifts towards lactate production.

Euglycaemic diabetic ketoacidosis is the second condition. Classically it is defined as ketoacidosis with glucose below 250 mg/dL, and the authors note it is increasingly recognised not only with SGLT2 inhibitors but also with GLP-1 receptor agonists, through appetite suppression, vomiting and reduced intake. Tirzepatide acts at that receptor among others.

The authors state that concurrent lactic acidosis and ketoacidosis with relative euglycaemia is exceedingly rare, and that no published synthesis of such cases exists to guide recognition or management. That absence is why the paper includes a literature review alongside the case.

Why the tirzepatide combination matters here

The mechanism the authors describe is not exotic. It is a chain of ordinary events.

Gastrointestinal side effects reduce food intake. Reduced intake and vomiting produce dehydration. Dehydration causes acute kidney injury. Impaired kidneys stop clearing metformin. Accumulated metformin drives lactate production while the reduced intake drives ketone production.

Every link in that chain is documented behaviour for metformin and tirzepatide taken together, which is what makes the combination worth naming rather than treating the case as a freak event.

The literature review the authors add is aimed at exactly this: they review reported cases of metformin-associated lactic acidosis with GLP-1 receptor agonist use to identify shared precipitants, risk factors and outcomes.

The part about the glucose reading

The authors state the key lesson themselves, and it is a diagnostic one.

In patients taking metformin alongside a GLP-1 receptor agonist, gastrointestinal side effects can precipitate lactic acidosis, while a disproportionately low glucose can mask the accompanying ketoacidosis.

A glucose measurement that looks reassuring is doing something worse than being unhelpful. It is actively pointing away from a diagnosis that is present. Ketoacidosis is normally suspected because glucose is high, and here the usual trigger for suspicion is absent.

Their recommendation follows from that: early measurement of serum beta-hydroxybutyrate, and prompt initiation of renal replacement therapy.

Beta-hydroxybutyrate is the ketone body that a bedside test measures directly, rather than inferring ketosis from glucose. The whole argument of the paper is that in this combination you have to measure the thing itself.

What a single tirzepatide case can and cannot support

One patient, recovered, written up because the combination is rare.

It cannot establish how often this happens, and the underlying condition is already rare: fewer than 10 per 100,000 patient-years for the lactic acidosis alone, before adding the requirement for concurrent ketoacidosis at normal glucose.

It cannot attribute cause between the two medicines either. Metformin is the agent that accumulates and drives lactate. Tirzepatide is the agent that reduces intake. Both contributed to a chain in which each depended on the other, and the report does not try to apportion blame between them.

The literature review is the part that carries more weight than the case, because it assembles what other reports have found rather than adding one more anecdote.

Where the tirzepatide case sits with the rest of this week

This is the second report in a week about ketone production following reduced intake on an incretin compound.

On Wednesday we covered a case report of a product bought online, in a man with type 1 diabetes whose ketonaemia reached 4.3 mmol/L after gastrointestinal illness. Different drug, different underlying condition, different supply route, same physiological sequence: intake drops, ketone production rises.

It also connects to a reflux signal across three national databases that we covered on Wednesday. Gastrointestinal effects with tirzepatide and its class are common, well documented and mostly treated as a tolerability issue. These two reports are about what happens when they stop being only a tolerability issue.

Against that, the cardiovascular indication approved last week came from a trial of more than 13,000 patients over four and a half years, where the safety profile was described as consistent with what was already known. Rare events do not show up in a summary like that, and case reports are how they surface.

What this means for the catalogue

Nothing in this tirzepatide report involves a compound used in a laboratory, and the transferable content is about how rare events enter the record.

A trial of 13,000 people will not reliably detect something occurring at fewer than 10 per 100,000 patient-years. Case reports and reporting databases are the instruments for that range, and they are the weakest instruments available, which is an uncomfortable but accurate description of how safety knowledge accumulates.

Retatrutide has no case report literature of this kind at all, and the reason is the same one we keep returning to: no approval means no prescribing, no prescribing means no clinical encounters, and no clinical encounters mean nothing to write up.

For laboratories, our European research buyer guide covers procurement and documentation, everything is supplied on a research use only basis, and our ranking of the most-studied research peptides counts primary studies for each compound.

References

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.

author-avatar

About Peptra Labs Research

The Peptra Labs research desk follows peptide science: new peer-reviewed studies, EU and US regulatory decisions, and clinical trial results. Every article cites its primary sources. All compounds discussed are for laboratory research use only.

Newer
GLP-1 in Resistant Hypertension: Equal BP, 4,153 Pairs
Back to list
Older GLP-1: WHO Guidelines, 1 Billion People, 3 Industries

Related Posts